AbSci Corp options imply significant post-earnings price movement.

AbSci Corp's pre-earnings options volume is 1.8x normal, with calls leading puts 11:1, and implied volatility suggests a 11.5% move in the share price after results are released. The median move over the past eight quarters is 3.9%.

AbSci Corp (ABSI) is set to release its Q2 2025 earnings on August 12, 2025. The market is anticipating a quarterly revenue of $1.43 million and an earnings per share (EPS) of -$0.21 [3]. The company has been under scrutiny for its financial performance and has faced several challenges, including increased research and development expenses and a decline in revenue.

The company reported a quarterly adjusted loss of 24 cents per share for the quarter ended June 30, 2025, which was lower than the same quarter last year but still missed the mean expectation of eight analysts for a loss of 21 cents per share [2]. The company's revenue fell 53.3% to $593,000, which was significantly lower than the expected $1.28 million [2].

Despite the financial setbacks, AbSci Corp has made significant strides in its drug discovery and development efforts. The company initiated Phase 1 clinical trials for ABS-101, a potential best-in-class anti-TL1A antibody, and plans to initiate a Phase 1 trial for ABS-201, an innovative anti-prolactin receptor antibody for androgenetic alopecia, in early 2026 [1]. These developments suggest a robust pipeline of promising drug candidates.

AbSci Corp's cash runway has been extended, with approximately $64 million in gross proceeds raised, strengthening its balance sheet and extending its cash runway into the first half of 2028 [1]. The company's strategic investment from AMD has also enhanced its capabilities in drug discovery, positioning it to remain competitive in the AI-based drug discovery landscape.

However, the company faces several challenges, including increased competition from big pharma companies with advanced AI-based drug discovery systems and a long development timeline for ABS-201, which suggests potential commercialization only by 2030-2031 [1]. Additionally, the company's stock has shown significant volatility, with pre-earnings options volume 1.8x normal, calls leading puts 11:1, and implied volatility suggesting a 11.5% move in the share price after results are released [Writing Topic].

In conclusion, AbSci Corp's Q2 2025 earnings report will provide insights into the company's financial health and its progress in drug discovery and development. The market is closely watching the company's performance, with analysts expecting a mixed bag of results and expectations. The company's ability to navigate these challenges and capitalize on its promising pipeline will be crucial for its future success.

References:
[1] https://finance.yahoo.com/news/absci-corp-absi-q2-2025-071232577.html
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U422P:0-absci-corp-reports-results-for-the-quarter-ended-june-30-earnings-summary/
[3] https://finance.yahoo.com/news/absci-corp-absi-q2-2025-133135146.html